创新药板块今日高开高走，关注恒生创新药ETF（159316）、创新药ETF易方达（516080）等投资价值

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 3.3%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 3%, indicating a positive trend in the Hong Kong pharmaceutical sector [1] - The China pharmaceutical industry has entered a critical phase characterized by "innovation realization + global layout," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] - By 2026, there are opportunities to focus on innovative commercialization, global breakthroughs, policy optimization, and industry mergers and acquisitions [1] Group 2 - The index focuses on leading stocks in the Hong Kong healthcare sector, comprising 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other healthcare industries [4] - The innovative drug ETF tracks the CSI Innovative Drug Industry Index, which includes no more than 50 companies involved in innovative drug research and development in the A-share market [6] - The biotechnology ETF tracks the CSI Biotechnology Theme Index, focusing on leading A-share companies involved in gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology [11]